Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Lyophilized Human Rabies Vaccine (Human Diploid Cell)
NCT07338786Phase 1Enrolling by invitation
- Sponsor
- Changchun BCHT Biotechnology Co.
- Start
- Sep 2025
- Primary completion
- Jan 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lyophilized human rabies vaccine in rabies, sponsored by Changchun BCHT Biotechnology Co. Primary endpoint: Safety Endpoints. Started Sep 2025; status: enrolling by invitation.
02
Drugs
lyophilized human rabies vaccine
03
Conditions
rabies
Beyond the preview
Go deeper on NCT07338786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07338786.